2021 年第一季度报告 公司代码：600664 公司简称：哈药股份 哈药集团股份有限公司 2021 年第一季度报告 1 / 19 2021 年第一季度报告 一、 二、 11Í 四、 目录 | --- | |----------------| | | | 重要提示 . | | 公司基本情况 . | | 重要事项 . | | 附录 . | 2 / 19 2021 年第一季度报告 一、 重要提示 1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 1.2 公司全体董事出席董事会审议季度报告。 1.3 公司负责人徐海瑛、主管会计工作负责人刘波及会计机构负责人（会计主管人员）魏巍保 证季度报告中财务报表的真实、准确、完整。 1.4 本公司第一季度报告未经审计。 二、 公司基本情况 2.1 主要财务数据 | --- | --- | --- | --- | |-----------------------------------------------|-------------------|----------- ...

2020 年年度报告 公司代码：600664 公司简称：哈药股份 哈药集团股份有限公司 2020 年年度报告 1 / 190 2020 年年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 北京兴华会计师事务所（特殊普通合伙）为本公司出具了标准无保留意见的审计报告。 四、 公司负责人徐海瑛、主管会计工作负责人刘波及会计机构负责人（会计主管人员）管平声明： 保证年度报告中财务报告的真实、准确、完整。 五、 经董事会审议的报告期利润分配预案或公积金转增股本预案 经北京兴华会计师事务所有限公司审计，公司2020年度母公司实现净利润-1,175,337,440.36 元，依照《公司法》和《公司章程》规定本年未提取法定盈余公积，加上年初未分配利润 -663,398,512.00元，2020年可供分配利润为-1,838,671,952.36元，因此本年度公司不实施利润 分配，也不进行资本公积金转增股本。本预案尚需提交公司年度股东大会审议。 六、 前瞻性陈述 ...

证券代码:600664 证券简称:哈药股份 编号:临 2020-052 哈药集团股份有限公司 关于参加投资者网上集体接待日活动的公告 | --- | --- | --- | |-------------------------------------------------------------------------|-------|------------------------------------------------------------------| | | | | | | | 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述 | | 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 | | | | | | 为进一步加强与投资者的互动交流，哈药集团股份有限公司（以 | | 下简称"公司"）将参加由黑龙江省上市公司协会、深圳市全景网络 | | | | 有限公司共同举办的"黑龙江省上市公司 2020 | | 年度投资者网上集体 | | 接待日"活动，现将有关事项公告如下： | | | | | | 本次集体接待日活动将通过深圳市全景网络有限公司提供的互 | | ...

2020 年第三季度报告 公司代码：600664 公司简称：哈药股份 哈药集团股份有限公司 2020 年第三季度报告 1 / 24 2020 年第三季度报告 重要提示 í in in 公司基本情况. 重要事项 四、 附录 目录 2 / 24 2020 年第三季度报告 一、重要提示 4.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 4.2 公司全体董事出席董事会审议季度报告。 4.3 公司负责人张镇平、主管会计工作负责人刘波及会计机构负责人（会计主管人员）管平保证 季度报告中财务报表的真实、准确、完整。 4.4 本公司第三季度报告未经审计。 二、公司基本情况 | --- | --- | --- | --- | |------------------------------------------------|------------------------------|------------------------------------|------------------------------- ...

Financial Performance - The company's operating revenue for the first half of 2020 was CNY 4,809,380,177.49, a decrease of 12.81% compared to CNY 5,516,041,838.19 in the same period last year[16]. - The net profit attributable to shareholders of the listed company was a loss of CNY 333,302,234.51, compared to a loss of CNY 42,347,051.96 in the previous year, representing a decline of 687.07%[16]. - The net cash flow from operating activities was a negative CNY 166,711,071.07, showing an improvement of 7.89% from a negative CNY 180,997,503.23 in the same period last year[16]. - The total assets at the end of the reporting period were CNY 10,794,684,609.50, down 13.66% from CNY 12,502,530,832.80 at the end of the previous year[16]. - The net assets attributable to shareholders of the listed company decreased to CNY 4,411,221,256.20, a decline of 19.16% compared to CNY 5,456,565,308.41 at the end of the previous year[16]. - Basic earnings per share for the first half of 2020 were -CNY 0.13, a decrease of 550.00% from -CNY 0.02 in the same period last year[17]. - The weighted average return on net assets was -7.56%, a decrease of 6.77 percentage points compared to -0.79% in the previous year[17]. - The company reported a net loss of CNY 1,129,140,214.49 for the first half of 2020, compared to a loss of CNY 663,398,512.00 in the same period of 2019[140]. - The total comprehensive income for the first half of 2020 was a loss of ¥1.01 billion, compared to a loss of ¥1.19 billion in the same period of 2019[145]. Operational Highlights - The company focuses on the pharmaceutical health industry, with 1,806 drug approvals and 83 health product approvals, covering areas such as anti-infection and cardiovascular treatments[21]. - The company expanded its marketing team and increased terminal coverage to enhance market access capabilities in response to the COVID-19 pandemic[27]. - The company has established over 70 production lines for various products, ensuring controlled production processes from raw material intake to finished product delivery[31]. - The company has a strong brand presence with five well-known trademarks and has received multiple awards, enhancing its market competitiveness[28]. - The company has 234 product specifications included in the national medical insurance directory, with a leading market share in certain antibiotic and health supplement categories[28]. - The company actively develops new sales channels and business models to mitigate the impact of the pandemic on physical pharmacy sales[27]. - The company is implementing cost control measures to reduce operational costs through various strategies[34]. - The company plans to enhance product marketing by leveraging high-quality products and expanding brand influence through centralized procurement[38]. Market and Industry Context - In the first half of 2020, the pharmaceutical manufacturing industry saw a revenue of approximately CNY 1,109.4 billion, a year-on-year decrease of 2.3%, while total profit increased by 2.1% to CNY 158.6 billion[26]. - The pharmaceutical manufacturing segment generated 1.301 billion yuan, while the pharmaceutical commercial segment accounted for 3.488 billion yuan[34]. - The company reported a significant increase in revenue from overseas markets, with a growth rate of 123.52% to approximately ¥39.73 million[51]. - The company aims to strengthen its pharmaceutical wholesale business by leveraging upstream resources and enhancing customer management[41]. Environmental and Social Responsibility - The company reported a chemical oxygen demand (COD) discharge concentration of 59.9 mg/L, which is below the permitted limit of 100 mg/L, with a total discharge of 2.29 tons for the first half of 2020[97]. - The ammonia nitrogen discharge concentration was recorded at 1.89 mg/L, significantly lower than the permitted limit of 8 mg/L, with a total discharge of 0.072 tons for the same period[101]. - The company has actively participated in social responsibility initiatives, including donating 125 N95 medical masks to the Yilan County People's Hospital during the pandemic[86]. - The company has reported a total of 100 individuals lifted out of poverty through its targeted poverty alleviation efforts[87]. - The company has established a sustainable industry project in Sixin Village, with an annual income of 280,000 RMB from the cultivation of artificial mushrooms, benefiting each poor household with over 3,000 RMB in dividends[90]. Financial Position and Liabilities - Total assets decreased from RMB 12.50 billion as of December 31, 2019, to RMB 10.79 billion as of June 30, 2020, representing a decline of approximately 13.76%[131]. - Total liabilities decreased from RMB 6.56 billion to RMB 5.89 billion, a decline of about 10.19%[131]. - The company's equity decreased to CNY 2,456,717,534.73 from CNY 3,634,530,038.89, a decline of approximately 32.4%[140]. - The company has recognized an impairment provision of approximately ¥171.41 million for its convertible preferred shares in GNC due to GNC's bankruptcy proceedings[55]. - The company has fully provided for impairment on receivable dividends from GNC, amounting to 171,414,381.09 RMB, which will be reflected in the current period's profit and loss[68]. Future Strategies and Developments - The company plans to focus on market expansion and new product development as part of its future strategy[141]. - The company is exploring potential mergers and acquisitions to enhance its market position and drive future growth[174]. - The company aims to leverage its product resources and brand advantages to strengthen its market position and competitiveness[28]. - The company is actively pursuing the development of generic and innovative drug projects to enrich its product pipeline[38]. Governance and Compliance - The financial statements are prepared based on the going concern principle and comply with the relevant accounting standards[179]. - The company confirms its ability to continue as a going concern for at least 12 months from the reporting date[180]. - The company has not made any changes to its important accounting policies and estimates during the reporting period[183]. - The company engages in various business activities, including drug production, sales, and technology development in the pharmaceutical sector[177].

2020 年第一季度报告 公司代码：600664 公司简称：哈药股份 哈药集团股份有限公司 2020 年第一季度报告 1 / 24 2020 年第一季度报告 一、 二、 11Í 四、 目录 | --- | |----------------| | | | 重要提示 . | | 公司基本情况 . | | 重要事项 . | | 附录 . | 2 / 24 2020 年第一季度报告 单位：元 币种：人民币 一、 重要提示 1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 1.2 公司全体董事出席董事会审议季度报告。 1.3 公司负责人张镇平、主管会计工作负责人刘波及会计机构负责人（会计主管人员）管平保证 季度报告中财务报表的真实、准确、完整。 1.4 本公司第一季度报告未经审计。 二、 公司基本情况 2.1 主要财务数据 2020 年一季度公司营业收入、归属于上市公司股东的净利润比去年同期有所降低，主要原因 如下： 疫情期间，零售端各类终端门店营业周期缩短、营业时间减少、与疫情相关的治疗领域药品 限售或禁售 ...

Financial Performance - In 2019, the company reported a net profit of -497,306,797.49 CNY, resulting in a total distributable profit of -663,398,512.00 CNY, leading to no profit distribution or capital reserve increase for the year [6]. - The company's operating revenue for 2019 was CNY 11,824,561,675.04, an increase of 9.35% compared to CNY 10,813,613,594.67 in 2018 [21]. - The net profit attributable to shareholders for 2019 was CNY 55,812,116.14, representing a significant decrease of 83.88% from CNY 346,139,970.93 in 2018 [21]. - The net cash flow from operating activities for 2019 was negative CNY 284,938,535.31, compared to positive CNY 692,724,935.55 in 2018 [21]. - The basic earnings per share for 2019 was CNY 0.02, down 85.71% from CNY 0.14 in 2018 [21]. - The total assets at the end of 2019 were CNY 12,502,530,832.80, an increase of 5.06% from CNY 11,900,901,626.53 at the end of 2018 [21]. - The company reported a net profit of CNY 51,555,047.80 in Q4 2019, following a net loss of CNY 145,155,449.90 in Q1 2019 [24]. - The company recorded non-recurring gains of CNY 67,960,359.17 in 2019, compared to CNY 102,013,850.29 in 2018 [24]. - The weighted average return on equity for 2019 was 0.94%, a decrease of 4.39 percentage points from 5.33% in 2018 [21]. - The gross profit margin for the main business decreased by 3.37 percentage points to 23.73% [40]. - The company achieved a revenue of 11.82 billion RMB, representing a year-on-year growth of 9.35% [36]. - The net profit attributable to shareholders of the listed company was 56 million RMB [36]. Audit and Compliance - The company’s financial report was audited by Beijing Xinghua Accounting Firm, which issued a standard unqualified opinion [5]. - The company has no major litigation or arbitration matters during the reporting period [140]. - The company has maintained a good integrity status with no issues reported for the controlling shareholders or actual controllers [140]. - The company has engaged Beijing Xinghua Accounting Firm for auditing services, with a remuneration of 80 thousand [140]. - The company has not faced any risks of suspension or termination of listing during the reporting period [140]. - The company has implemented new financial instrument standards since January 1, 2019, with adjustments made to financial statement items as per the new regulations [136]. - The adjustments due to the new financial instrument standards affected the consolidated financial statements, with accounts receivable and accounts payable showing significant changes [136]. Market and Industry Position - The company focuses on the pharmaceutical health industry, with a product range including 347 specifications in areas such as anti-infection, cardiovascular, and oncology drugs [28]. - The company’s core products, including penicillin and cephalosporin antibiotics, have a leading market share in their respective segments [31]. - The company has 233 product specifications listed in the 2019 National Medical Insurance Directory, enhancing its market presence [32]. - The pharmaceutical manufacturing industry achieved a revenue of CNY 2,390.86 billion in 2019, with a year-on-year growth of 7.4% [28]. - The company holds a significant position in the domestic antibiotic market, with a product cluster that includes various potential varieties such as fourth-generation cephalosporins and new β-lactam antibiotics [63]. - The company has a strong market share in high-quality chemical preparations, including products like Amoxicillin capsules and Ceftriaxone sodium for injection, particularly in the fields of anti-infection and cardiovascular health [63]. Research and Development - The R&D expenses amounted to CNY 125,142,270.21, a decrease of 8.83% compared to the previous year [40]. - Total R&D investment amounted to 135,430,228.17 yuan, representing 1.15% of operating revenue [52]. - The number of R&D personnel is 224, making up 1.57% of the total workforce [52]. - The company is advancing consistency evaluation work, with 6 products entering the review stage and 32 products progressing in the evaluation process [35]. - The company plans to enhance product consistency evaluation to improve drug access and cost control, aiming for sustainable sales growth [71]. - Research and development efforts have led to two products passing the national consistency evaluation, with ongoing studies for new drug classifications [85]. - The company is committed to improving its research and quality control processes in traditional Chinese medicine to adapt to market developments and regulatory changes [63]. Operational Efficiency and Strategy - The company has implemented a market-oriented management team and restructured its marketing system to improve operational efficiency [31]. - The company is focusing on talent acquisition, optimizing organizational structure, and enhancing management efficiency [35]. - The company is actively managing accounts receivable and inventory to improve cash flow and reduce inventory turnover days [35]. - The company is expanding its e-commerce platform and diversifying sales channels to strengthen market coverage [35]. - The company has refined its customer cooperation and product structure, enhancing sales channel development and brand building [100]. - The company has implemented a sales model combining self-operated teams and specialized distributors, enhancing market coverage and core competitiveness [100]. Environmental Responsibility - The company has established a quality assurance system in line with GMP standards, but still faces quality risks due to uncertainties in raw material procurement and logistics [120]. - The company has installed an online monitoring system for wastewater discharge at three outlets, ensuring compliance with environmental standards [167]. - The company operates two wastewater treatment systems with a combined design capacity of 25,000 tons per day, both functioning normally [167]. - The company has implemented a comprehensive environmental risk emergency mechanism and developed an emergency response plan for sudden environmental pollution incidents [172]. - The company’s environmental management system has been re-certified according to GB/T24001-2016/ISO14001:2015 standards, indicating effective operation [176]. Social Responsibility - The company established the "Harbin Pharmaceutical Public Welfare Foundation" to promote social responsibility and engage in various charitable activities [161]. - The company donated a total of 235,000 RMB in cash and 132,900 RMB in materials for poverty alleviation efforts, benefiting 743 registered impoverished individuals [155]. - The company plans to enhance its support for impoverished households by providing medical assistance and training for agricultural projects, aiming to reduce poverty caused by illness [160]. - The company has actively engaged in social responsibility initiatives, including education support, poverty alleviation, and medical assistance [161]. Shareholder and Capital Structure - The company completed the repurchase and cancellation of 21,561,100 restricted shares on January 15, 2019, and an additional 16,373,100 shares on October 17, 2019 [142][145]. - The controlling shareholder, Harbin Pharmaceutical Group, increased its shareholding ratio from 46.49% to 46.80% [185]. - The total number of ordinary shareholders at the end of the reporting period was 100,241, down from 161,125 at the end of the previous month [185]. - The company’s stock structure post-capital increase includes Harbin State-owned Assets Commission, CITIC Iceland, Huaping Iceland, and others, with the largest shareholder holding 38.25% [197]. - The company has not reported any changes in the actual controller situation during the reporting period [195].

2019 年第三季度报告 公司代码：600664 公司简称：哈药股份 哈药集团股份有限公司 2019 年第三季度报告 1 / 26 2019 年第三季度报告 一、 重要提示 二、 公司基本情况. 11[ 重要事项 四、 附录 目录 2 / 26 2019 年第三季度报告 单位：元 币种：人民币 一、 重要提示 1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 1.2 公司全体董事出席董事会审议季度报告。 1.3 公司负责人张镇平、主管会计工作负责人刘波及会计机构负责人（会计主管人员）管平保证 季度报告中财务报表的真实、准确、完整。 1.4 本公司第三季度报告未经审计。 二、 公司基本情况 2.1 主要财务数据 | --- | --- | --- | --- | |-----------------------------------------------|------------------------------|------------------------------------|----- ...

2019 年半年度报告 公司代码：600664 公司简称：哈药股份 哈药集团股份有限公司 2019 年半年度报告 1/162 2019 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实、 准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法 律责任。 二、 公司全体董事出席董事会会议。 三、 本半年度报告未经审计。 四、 公司负责人张镇平、主管会计工作负责人刘波及会计机构负责人（会计主管人员） 管平声明：保证半年度报告中财务报告的真实、准确、完整。 五、 经董事会审议的报告期利润分配预案或公积金转增股本预案 无 六、 前瞻性陈述的风险声明 √适用 □不适用 本公司2019年半年度报告涉及的公司未来计划、发展战略等前瞻性描述不构成公 司对投资者的实质承诺，敬请投资者注意投资风险。 七、 是否存在被控股股东及其关联方非经营性占用资金情况 否 八、 是否存在违反规定决策程序对外提供担保的情况？ 否 九、 重大风险提示 报告期内，不存在对公司生产经营产生实质性影响的特别重大风险。公司已在本 报告中详细阐述公司在生产经营过程中面临的各种风险及应对措施 ...

证券代码:600664 证券简称:哈药股份 编号:临 2019-032 哈药集团股份有限公司 关于参加投资者网上集体接待日活动的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 为进一步加强与投资者的互动交流，哈药集团股份有限公司（以 下简称"公司"）将参加由黑龙江省上市公司协会、深圳市全景网络 有限公司共同举办的"2019年黑龙江省上市公司投资者网上集体接待 日"活动，现将有关事项公告如下： 本次集体接待日活动将通过深圳市全景网络有限公司提供的互 联 网 平 台 举 行 ， 投 资 者 可 以 登 陆 " 全 景 · 路 演 天 下 " 网 站 （http://rs.p5w.net）参与公司本次投资者集体接待日活动,时间为 2019年6月19日（周三）14:00至16:30。 届时公司董事、副总经理、总会计师刘波先生及董事、副总经理、 董事会秘书孟晓东先生将通过网络在线问答互动的形式，与投资者就 公司治理、发展经营情况、融资情况和可持续发展等投资者关注的问 题进行交流。期间，公司高管将全程在线，实时回答投资者的提问。 ...